Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLMartin Reck, Christian Manegold, Joachim von Pawel et al.|Journal of Clinical Oncology|2009Cited by 1.5k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker, U. Gatzemeier, Jose R. Pereira et al.|The Lancet|2009Cited by 1.4k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupFrank V. Fossella, Chandra P. Belani, Jose R. Pereira et al.|Journal of Clinical Oncology|2003Cited by 943
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation TrialU. Gatzemeier, Joachim von Pawel, A Płużańska et al.|Journal of Clinical Oncology|2007Cited by 879
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Martin Reck, C. Manegold, Joachim von Pawel et al.|Annals of Oncology|2010Cited by 644